Abstract 1746P
Background
On-call work is an inherent component of Oncology care. Managerial models focus on length of stay in calculating efficiency within hospitals. Ensuring compliance with the European Working Time Directives (EWTD) for doctors is a legal requirement for Hospitals. Calculations of required physician staff to provide overnight care is not necessarily based on numbers of patients to be cared for, nor the complexity of care. The acute oncology service (AOS) after-hours has to date been provided by the day-time medical team in whole. To improve safety and quality of the AOS for patients being seen after hours, as well as to comply with the EWTD, a change to shift-work for the 1st-on-call oncology doctor is planned in 7/23. We sought to quantify the impact on the service.
Methods
The numbers of non-consultant hospital doctors (NCHDs), with allowances for full staff and also allowing for annual and educational leave entitlements were gathered for 1) pre-shift work implementation and 2) post-implementation of shift work. The number of NCHDs multiplied by the hours available to the ambulatory services (day unit and outpatient clinics) were calculated per week for both service structures to produce the "available NCHD hours".
Results
Assuming the normal working day is 8am to 5pm, this change would result in the reduction of available NCHDs to the ambulatory oncology service from 270 available NCHD hours per week to 171 available NCHD hours once vacation and study leave are factored into the equation, despite the addition of one NCHD to the medical oncology team. This represents a 36% reduction in available staff yet with a likely continued increase in patient activity.
Conclusions
While modifying the after-hours service to shift-work augments availability of medical staff for the acutely unwell patient with cancer and achieves compliance with EWTD, it reduces the numbers of doctors available for a significant part of the day, placing more strain on those doctors trying to manage a similar number of patients in a safe and patient-focused manner. Changes to the after-hours service inadvertently has knock-on effects on the “Oncology Ecosystem” and may impact on future service quality. Adjustments to NCHD numbers to cover the predicted significant staff fall short of those required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont RCSI Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23